Trending Down-0.0800 (-5.8394%)
  • Bid / Lots
    1.2900/ 38
  • Ask / Lots
    1.3200/ 4
  • Open / Previous Close
    1.3400 / 1.3700
  • Day Range
    Low 1.2900
    High 1.3700
  • 52 Week Range
    Low 0.7277
    High 19.1400
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.37
09:32 ET31231.3528
09:34 ET3981.3675
09:36 ET1951.3685
09:38 ET5001.37
09:39 ET6851.3601
09:41 ET12501.365
09:43 ET6001.3693
09:45 ET3121.37
09:50 ET3951.3608
09:52 ET2501.3608
09:54 ET19641.34
09:56 ET25001.3377
09:57 ET42541.34
09:59 ET11501.3461
10:01 ET29201.35
10:03 ET1001.35
10:06 ET7581.34
10:08 ET3001.35
10:10 ET8221.34
10:12 ET1001.34
10:14 ET1001.34
10:17 ET13191.345
10:19 ET15001.34
10:21 ET2001.33
10:24 ET2001.32
10:28 ET17021.31
10:30 ET1001.31
10:32 ET3001.3109
10:33 ET2601.3026
10:35 ET19041.3
10:39 ET34351.3
10:44 ET1001.3
10:46 ET1001.305
10:48 ET27681.3
10:50 ET2001.3
10:51 ET1001.3
10:53 ET5641.3
10:57 ET11161.3
11:11 ET1001.3
11:13 ET2001.3
11:20 ET7701.3066
11:22 ET13001.3048
11:24 ET3001.3085
11:26 ET7001.3
11:31 ET7001.3
11:36 ET1001.31
11:38 ET8001.32
11:40 ET1001.29
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAPLT
Applied Therapeutics Inc
United StatesELEV
Elevation Oncology Inc
United StatesCNTX
Context Therapeutics Inc
United StatesTXTM
Protext Mobility Inc
United StatesCLBS
Caladrius Biosciences Inc
United StatesIMRA
Imara Inc
As of 2022-08-16

Company Information

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

Contact Information

545 5TH AVENUE, SUITE 1400NEW YORK, NY, United States 10017


Chairman of the Board, President, Chief Executive Officer, Founder
Shoshana Shendelman
Chief Commercial Officer
Adam Hansard
Chief Medical Officer
Riccardo Perfetti
Lead Independent Director
Teena Lerner
Independent Director
Leslie Funtleyder

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.